What it is
5-Amino-1MQ is NOT a peptide. Peptides are short chains of amino acids. 5-Amino-1MQ is a small chemical built on a two-ring structure called quinoline (it is a methylquinolinium), made in a laboratory. It is often sold next to peptides by the same online sellers, which is why it appears on this site. Its full chemical name is 5-amino-1-methylquinolinium. It carries a positive electrical charge, so it is normally made and supplied as a salt with iodide.
More on what it is and where it came from
It blocks an enzyme called nicotinamide N-methyltransferase, or NNMT for short. An enzyme is a protein that speeds up a chemical reaction in the body. NNMT is found in fat tissue and the liver, among other places.
All published results come from cells and animals, mainly mice. It has never been tested in a published or registered human study, and no medicine containing it is approved in any country we checked.
5-Amino-1MQ came out of a drug-discovery project at the University of Texas Medical Branch (UTMB) in Galveston, led by Stanley Watowich with Harshini Neelakantan, working with chemists at the University of Texas at San Antonio. In 2017 the group published a study comparing many small molecules that block NNMT and reported that the methylquinolinium family looked most promising. In 2018 they reported that 5-amino-1MQ reduced fat in obese mice. Watowich later founded a company, Ridgeline Therapeutics in Houston, and the later mouse papers (2021 to 2026) list him as its founder and Neelakantan as an employee. In a 2019 company announcement, Ridgeline said it was preparing human trials of a related NNMT blocker called RLT-72484; we found no such trial registered.
How it is thought to work
NNMT attaches a small chemical tag (a methyl group) to nicotinamide, a form of vitamin B3. It takes that tag from a molecule called SAM, the body's main tag donor. In 2014 a Harvard team reported that switching NNMT down in the fat and liver of mice protected them from becoming obese on a fatty diet, by raising the energy their cells burned. A 2015 German study of 314 people linked higher NNMT activity in fat tissue, and more of its product in blood, with type 2 diabetes and insulin resistance. That is why researchers wondered whether blocking NNMT with a drug could help with obesity.
More on how it works
The UTMB group proposed that blocking NNMT leaves more nicotinamide available to make NAD+ (a molecule cells use to handle energy) and keeps more SAM. In fat cells grown in a dish, 5-amino-1MQ lowered NNMT's product, raised NAD+ and SAM, and reduced fat-making. The authors said they had not yet confirmed those chemical changes in the fat of living animals. A 2025 study complicates the picture: in aged mice, a different NNMT blocker (AMO-NAM, not 5-amino-1MQ) sharply lowered NNMT's product but did not raise NAD levels.
In old mice, the same group reported that it woke up dormant muscle stem cells after an injury. How this happens is, in the authors' words, currently unknown. A 2024 test also found that the molecule partly blocks a second enzyme, MAO-A, and the authors suggested this might contribute to some of the effects on blood sugar. So the effects in mice may not all come from NNMT.
What is established in people
Nothing is established in people. On 18 November 2026 I searched PubMed and ClinicalTrials.gov and found no published or registered human study of 5-amino-1MQ or of any other NNMT-blocking drug. The only human research on NNMT is observational: it measured the enzyme in people's fat tissue and linked higher levels to type 2 diabetes and insulin resistance, which shows an association, not that blocking it helps. Every result for 5-amino-1MQ itself comes from mice, rats or cells, in studies lasting from 11 days to 8 weeks with groups of roughly 6 to 13 animals.
What the studies found
13 studies, human trials first. Each links to the paper or registry record.
- Animal study2026
NNMT inhibition counteracts tubular senescence and fibrosis in early stages of chronic kidney disease.
The authors linked NNMT in kidney tubules to ageing of kidney cells, scarring and loss of kidney function in human biopsies, and reported that 'selective NNMT inhibition' was protective in cells, organoids and mice.
Full finding, who was studied, and limits
Who: Human kidney biopsy data, kidney cells, lab-grown mini-kidneys (organoids), and old or diabetic mice. Nestle Research, Amsterdam UMC and others, with Ridgeline co-authors. The abstract does not give animal numbers.
The authors linked NNMT in kidney tubules to ageing of kidney cells, scarring and loss of kidney function in human biopsies, and reported that 'selective NNMT inhibition' was protective in cells, organoids and mice.
Read with care: The abstract does not name which NNMT blocker was used, so it may not be 5-amino-1MQ. Animal and lab work only. I could not open the full text.
- Animal study2026
Nicotinamide N-Methyltransferase Inhibition Mitigates Cerulein-Induced Pancreatic Fibrosis via Galectin-3-Mediated Regulation of Stellate Cell Activation and Macrophage M2 Polarization in Mice.
NNMT was raised in the inflamed pancreas, especially in the cells that make scar tissue.
Full finding, who was studied, and limits
Who: Female mice with chronic pancreatitis (long-term inflammation and scarring of the pancreas) caused by a chemical, 108 mice in total, and pancreas support cells grown in the lab. The NNMT blocker used was 5-amino-1-methylquinolinium iodide (5-amino-1MQ itself), bought from a chemical supplier (Macklin). Run at Sun Yat-sen University hospitals, Shenzhen, China; funded by Chinese public research programmes.
NNMT was raised in the inflamed pancreas, especially in the cells that make scar tissue. Blocking NNMT, either genetically or with 5-amino-1MQ, made those cells less active and slowed their growth and movement in the lab. In the mice, 28 days of 5-amino-1MQ reduced collagen (scar tissue) in the pancreas and shifted immune cells away from a scar-promoting state. The authors traced the effect to reduced production of a protein called galectin-3.
Read with care: Mice and lab cells only, one chemically induced model. Group sizes per treatment are not clearly stated. Shows less scarring, not better pancreas function or survival. Nothing about people.
- Animal study2025
Nicotinamide N-methyltransferase inhibition improves limb function in experimental peripheral artery disease.
NNMT levels were higher in leg muscle from patients with peripheral artery disease and stayed high in mouse muscle stem cells after the blockage.
Full finding, who was studied, and limits
Who: Male mice with blood flow to one leg cut off surgically (a model of peripheral artery disease, narrowed leg arteries), randomly given an NNMT blocker or placebo; the abstract says 24 mice, the methods say 19, and figures show 9 placebo and 12 treated. Also existing data on leg muscle from patients with and without the disease. The blocker is NOT named as 5-amino-1MQ: the paper calls it 'a potent NNMT inhibitor' with a supplier catalogue number (MedChemExpress HY-131042). Run at the University of Florida; funded by the US National Institutes of Health and the American Heart Association.
NNMT levels were higher in leg muscle from patients with peripheral artery disease and stayed high in mouse muscle stem cells after the blockage. The NNMT blocker did not improve blood flow recovery, small blood vessel numbers, muscle mass or fibre size, but treated mice had stronger muscles (absolute force p < 0.0001, force per muscle size p = 0.0035) and did more work in a six-minute limb test (p = 0.037). Tissue death trended lower (p = 0.08, not significant).
Read with care: Mice only, and the inhibitor's chemical identity is not given, so it may not be 5-amino-1MQ. The paper's mouse numbers are inconsistent. Gains were in strength, not blood flow. The patient data only show NNMT levels; no patient received any NNMT blocker.
- Animal study2025
Nicotinamide-N-methyltransferase inhibition improves cardiac function and structure in a heart failure with preserved ejection fraction mouse model.
The heart-failure mice had more than double the normal level of NNMT's product, 1-MNA (up 121.6%).
Full finding, who was studied, and limits
Who: A DIFFERENT NNMT BLOCKER, not 5-amino-1MQ: 4-amino-6-methoxynicotinamide (AMO-NAM), developed by AstraZeneca. Aged female mice (18 to 22 months) given a high-fat diet and other stresses to develop a stiff-heart type of heart failure (heart failure with preserved ejection fraction), treated for four weeks. Run at University Medical Center Groningen, the Netherlands, with AstraZeneca scientists as co-authors.
The heart-failure mice had more than double the normal level of NNMT's product, 1-MNA (up 121.6%). AMO-NAM cut 1-MNA by 77.1% and two related breakdown products by about two-thirds, but did not change NAD levels. Heart function measures improved, heart muscle thickening and scarring decreased, and inflammation and immune-cell build-up in the heart and belly fat fell.
Read with care: Mice only, a different molecule from 5-amino-1MQ, and short treatment. Notably, blocking NNMT did not raise NAD in this model, though raising NAD is the reason usually given online for 5-amino-1MQ. Several authors are AstraZeneca employees, the company that made the compound. Group sizes are not given in the abstract.
- Animal study2024
Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice.
Grip strength was about 40% higher with 5-amino-1MQ alone, about 20% higher with exercise alone and about 60% higher with both, compared with sedentary controls.
Full finding, who was studied, and limits
Who: 35 female mice aged 22 months at the start, for 8 weeks: sedentary with salt water (9), sedentary with 5-amino-1MQ (9), weighted wheel running with salt water (10), running with 5-amino-1MQ (7). Daily injection under the skin. Ridgeline Therapeutics, University of Kentucky and UTMB.
Grip strength was about 40% higher with 5-amino-1MQ alone, about 20% higher with exercise alone and about 60% higher with both, compared with sedentary controls. Fat inside muscle fell by more than 30% in sedentary treated mice. Peak force of the calf muscles did not change with either treatment. The measured half-life in the blood was about 7 hours.
Read with care: Females only, small groups, and treated groups were about 10% heavier at the start. Grip strength did not match the calf-force results. Protein findings were not corrected for multiple testing. There was no formal safety analysis. Two authors were Ridgeline employees and one its founder.
- Animal study2024
Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction.
Treated mice on the higher amount gained 0.9 g versus 5.4 g in controls, with less fat gain, better blood-sugar handling and less fat in the liver (one measure fell 73%).
Full finding, who was studied, and limits
Who: Male obese mice (C57BL/6) on a high-fat diet, 8 per group (control and two amounts of 5-amino-1MQ), daily injection under the skin for about 28 to 30 days (the abstract says 28, the methods 30). A small blood-level study in 3 mice also tested it by mouth. Ridgeline Therapeutics and UTMB.
Treated mice on the higher amount gained 0.9 g versus 5.4 g in controls, with less fat gain, better blood-sugar handling and less fat in the liver (one measure fell 73%). Liver enzyme levels in blood (ALT) dropped. In a lab screen of other targets the molecule showed little activity except 67.4% blocking of MAO-A, an enzyme that breaks down mood and blood-pressure chemicals. Oral uptake in mice was 3.5%.
Read with care: Males only, 8 per group, about one month. No dedicated toxicity study. The authors said work was ongoing to fix the molecule's fast clearance in mice and its off-target action on MAO-A. All but one author were current or former Ridgeline staff or its founder.
- Animal study2024
NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer
High NNMT in the support cells around tumours was linked to worse outcomes in patients.
Full finding, who was studied, and limits
Who: Bladder cancer tissue from patients, plus young mice (C57BL/6) with implanted bladder tumours, 6 per group (10 per group in a second experiment), followed for 19 days. Sun Yat-sen University, China, a group independent of UTMB and Ridgeline.
High NNMT in the support cells around tumours was linked to worse outcomes in patients. In mice, 5-amino-1-methylquinolinium iodide reduced tumour size and changed the immune cells in the tumour. The authors reported a trend toward a bigger effect when combined with an immunotherapy drug.
Read with care: Mice with implanted tumours, not patients. It shows that independent labs use 5-amino-1MQ as a research tool, in a different field (cancer), not that it treats cancer. Safety and body weight were not reported in the part of the paper I read.
- Animal study2021
Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice.
Mice on the lean diet plus 5-amino-1MQ lost 6.3 g of body weight versus 2.9 g on the lean diet alone, and lost about 29% of their fat mass versus about 3%.
Full finding, who was studied, and limits
Who: Male obese mice (C57BL/6J) switched from a Western-style diet to a lean diet, with or without daily 5-amino-1MQ, for about 7 weeks; about 6 to 8 mice per group, compared with mice kept lean throughout.
Mice on the lean diet plus 5-amino-1MQ lost 6.3 g of body weight versus 2.9 g on the lean diet alone, and lost about 29% of their fat mass versus about 3%. Their body make-up and liver fat ended up close to mice that had always been lean. Food intake did not differ. The authors reported no adverse effects and most blood chemistry values did not differ.
Read with care: Small groups, males only, and blood tests in only 3 to 6 mice per group. Some findings did not survive correction for multiple testing. Two authors had ties to Ridgeline Therapeutics, the company developing NNMT blockers.
- Animal study2021
Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies.
The authors built a lab test to measure the molecule in rat blood and urine.
Full finding, who was studied, and limits
Who: Rats given 5-amino-1MQ into a vein or by mouth, to measure how much reached the blood. Texas Southern University with UTMB co-authors. The abstract does not give the number of rats.
The authors built a lab test to measure the molecule in rat blood and urine. They reported 'a good oral bioavailability (F % = 38.4)', meaning about 38% of a swallowed amount reached the bloodstream in rats.
Read with care: Rats, not people. A 2024 study by the UTMB group measured oral uptake in mice at only 3.5% and said the molecule is cleared quickly in mice. How much reaches the blood when a person swallows it has never been measured.
Journal of Pharmaceutical and Biomedical Analysis · pubmed.ncbi.nlm.nih.gov
- Animal study2019
Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle.
Treated mice had more active muscle stem cells (about 60% to 75% more), and the repaired muscle fibres were 1.8 times thicker at one week and 1.5 times thicker at three weeks.
Full finding, who was studied, and limits
Who: Male mice aged 24 months (old for a mouse) whose shin muscle was injured with a chemical (barium chloride). Main study 48 mice: 13 controls, 10 on a lower amount and 13 on a higher amount of 5-amino-1MQ, for 2 weeks. A second group of 6 controls and 6 treated mice was followed for 4 weeks. Given by injection under the skin. University of Texas Medical Branch.
Treated mice had more active muscle stem cells (about 60% to 75% more), and the repaired muscle fibres were 1.8 times thicker at one week and 1.5 times thicker at three weeks. Peak muscle force adjusted for body weight was 67% higher. Force adjusted for fibre size did not differ. A blood chemistry panel in 4 mice per group showed no significant differences, and the authors described the treatment as well tolerated.
Read with care: Old male mice with a chemical injury, not people with age-related muscle loss. Small groups; some results were borderline (one fusion result had p = 0.069). The total number of muscle stem cells did not change. The authors said how it works is unknown and that longer-term effects and safety still need study.
- Animal study2018
Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.
Treated mice lost about 5.1% of their body weight while control mice gained about 1.4%.
Full finding, who was studied, and limits
Who: Male mice made obese on a high-fat diet (C57BL/6), about 17 weeks old, 9 given 5-amino-1MQ by injection under the skin and 9 given salt water, for 11 days. Also fat cells grown in a dish. University of Texas Medical Branch.
Treated mice lost about 5.1% of their body weight while control mice gained about 1.4%. The main belly fat pad was about 35% lighter, fat cells were more than 30% smaller and blood cholesterol was about 30% lower. Food intake did not differ. In the dish, the molecule entered cells, did not block several related enzymes tested, raised NAD+ and SAM, and reduced fat-making.
Read with care: Nine mice per group, males only, for 11 days. Tolerability was judged from observation and a two-mouse pilot; no formal toxicology was done. The authors called this a short proof-of-concept and said the chemical changes in living fat tissue were not yet confirmed. Triglyceride results were lost because of damaged samples.
- Animal study2014
Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.
The authors wrote that NNMT uses SAM to add a methyl tag to nicotinamide (vitamin B3), and that switching NNMT down in fat and liver 'protects against diet-induced obesity by augmenting cellular energy expenditure'.
Full finding, who was studied, and limits
Who: Mice on a high-fat diet in which NNMT was switched down in fat tissue and liver using a genetic tool (antisense). Beth Israel Deaconess Medical Center and Harvard Medical School. This study did not use 5-amino-1MQ.
The authors wrote that NNMT uses SAM to add a methyl tag to nicotinamide (vitamin B3), and that switching NNMT down in fat and liver 'protects against diet-induced obesity by augmenting cellular energy expenditure'. This is the main reason NNMT became a drug target for obesity.
Read with care: Mice, not people. It used a genetic method to lower NNMT, not a drug, so it does not show that a pill or injection that blocks NNMT would work or be safe.
- Cell study2017
Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase.
The group compared related chemicals (quinoliniums, isoquinoliniums, pyridiniums and others) and found their strength at blocking NNMT varied more than 1,000-fold.
Full finding, who was studied, and limits
Who: Laboratory tests of the purified NNMT enzyme with several families of small molecules, plus computer modelling. University of Texas Medical Branch and University of Texas at San Antonio. No animals or people.
The group compared related chemicals (quinoliniums, isoquinoliniums, pyridiniums and others) and found their strength at blocking NNMT varied more than 1,000-fold. The quinolinium family was the most promising. Computer modelling suggested these molecules sit in the spot where nicotinamide normally binds on the enzyme.
Read with care: Test-tube chemistry only. The abstract does not name 5-amino-1MQ specifically. PubChem lists the synonym 'Compound 1k, NNMT inhibitor' for the iodide salt, which suggests it was one of this paper's compounds, but I could not open the full text to confirm.
Safety findings
- No human safety data exist. No human study of 5-amino-1MQ has been published or registered. Source: clinicaltrials.gov
- In obese mice treated for 11 days, the authors reported no observable side effects and no change in food intake. Tolerability was checked by observation and a two-mouse pilot; no formal toxicology study was done. In fat cells in a dish, high concentrations killed some cells. Source: pmc.ncbi.nlm.nih.gov
- In 24-month-old mice, a blood chemistry panel (4 mice per group) showed no significant differences between treated and untreated animals, and the authors described the treatment as well tolerated with no behavioural effects. Source: pmc.ncbi.nlm.nih.gov
- Off-target effect: in a 2024 lab screen the molecule blocked monoamine oxidase A (MAO-A) by 67.4%. MAO-A breaks down chemical messengers such as serotonin and noradrenaline, and medicines that block it can interact with other drugs and some foods. Whether this matters in people is unknown; the authors said they were working to remove this off-target action. Source: pmc.ncbi.nlm.nih.gov
3 more safety findings
- How the body handles it differs between species. About 38% of a swallowed amount reached the blood in rats but only 3.5% in mice, and mice cleared it quickly. Nothing is known about absorption, clearance or build-up in people. Source: pubmed.ncbi.nlm.nih.gov
- Long-term effects are unknown. The longest published treatment was 8 weeks in mice. No studies of cancer risk, fertility or pregnancy were found. The authors of the 8-week study said longer treatment still needs study. Source: pmc.ncbi.nlm.nih.gov
- Product quality: the January 2026 FDA warning letter to a compounding company that used 5-amino-1MQ iodide also cited problems with sterile manufacturing at that facility. Source: fda.gov
Rules and status
Not an FDA-approved drug. Not on the FDA's list of substances that pharmacies may compound from under section 503A, and not on the 503B list for outsourcing facilities. In January 2026 the FDA warned a compounding company for making products with it.
The full history, with dates
Approval: no FDA-approved drug contains 5-amino-1MQ, and we found no approval in any other country. Compounding: it does not appear in the FDA's list of nominated 503A bulk substances by category (updated 14 May 2026), so it has not been nominated for, or placed in, Category 1 or Category 2. It is not on the FDA page of bulk substances that may present significant safety risks (current as of 22 April 2026). It is not among the substances on the 503A bulks list in federal regulations (21 CFR 216.23(a)). It is not one of the six peptides named in the draft HHS enforcement-discretion policy announced on 30 October 2026 (91 FR 68526), which in any case covers only certain peptides. FDA statement: on 20 January 2026 the FDA issued a warning letter to GenoGenix LLC, an outsourcing facility in Boca Raton, Florida, stating that it had compounded drug products using bulk substances not eligible under section 503B, 'including 5-amino-1-methylquinolinium iodide (5-Amino-1MQ)', and that 5-Amino-1MQ does not 'appear on the 503B bulks list'. The letter says the firm had stopped making and distributing drugs. Dietary ingredient status: I found no FDA record of a new dietary ingredient notification for 5-amino-1MQ and no FDA statement on whether it can be sold as a dietary supplement, so its status as a supplement ingredient could not be sourced. The FDA's substance registry assigns it an identifier (UNII PMX593N4N3); that is a naming code, not an approval.
Source: fda.gov (source dated 2026-01-20)
In sport: Not named on the WADA 2026 or 2027 Prohibited Lists. Class S0 (Non-approved substances) prohibits at all times any pharmacological substance not covered elsewhere on the List that has no current approval by any government health regulator for human therapeutic use, including drugs under pre-clinical development. 5-Amino-1MQ is not named; S0 applies if it has no approval anywhere, and we found no approval in any country. It is not listed under S4.4 metabolic modulators. WADA
Claims and what the evidence supports
| What people say | What the evidence supports |
|---|---|
| 5-Amino-1MQ is a peptide. | It is not. It is a small synthetic molecule (a methylquinolinium) with a molecular weight of about 159 g/mol for the active part, far smaller than any peptide on this site. It is sold alongside peptides, which causes the confusion. Source: pubchem.ncbi.nlm.nih.gov |
| It melts fat and causes weight loss in people. | It has never been tested in people. In obese male mice it reduced body weight by about 5% over 11 days and limited fat gain over about a month, in groups of 8 or 9 animals. Mouse obesity results often do not carry over to humans. Source: pmc.ncbi.nlm.nih.gov |
| It reverses muscle ageing and builds strength. | In old mice it helped chemically injured muscle repair and raised grip strength, but in the 2024 study it did not change peak calf-muscle force. There are no human data. Source: pmc.ncbi.nlm.nih.gov |
| It works by boosting NAD+. | NAD+ rose in fat cells grown in a dish. The authors said this had not been confirmed in the fat of living animals, and a 2024 study found the molecule also blocks another enzyme, MAO-A, that may explain some effects. Source: pmc.ncbi.nlm.nih.gov |
| It is proven safe because the mouse studies saw no side effects. | The mouse studies were short (11 days to 8 weeks), small and did not include formal toxicology. No human has been studied, and the 2024 off-target finding on MAO-A is an unanswered safety question. Source: pmc.ncbi.nlm.nih.gov |
| It works well taken by mouth. | Animal results conflict: about 38% reached the blood after swallowing in rats, but only 3.5% in mice. Nothing has been measured in people. Source: pubmed.ncbi.nlm.nih.gov |
| It is legal for pharmacies to make or is in clinical trials. | It is not on any FDA compounding list, and the FDA warned a compounding company in January 2026 for using it. No human trial is registered on ClinicalTrials.gov. Source: fda.gov |
What a genuine lab report should show
- Identity by mass spectrometry: the measured mass should match the 5-amino-1-methylquinolinium cation, formula C10H11N2+, about 159.2 g/mol. The report should also confirm the structure, for example by NMR (a method that maps the atoms in a molecule).
- The report should say which salt was tested. The iodide salt (C10H11IN2, about 286.1 g/mol, CAS 42464-96-0) is the form named in the FDA warning letter and most research papers; a chloride salt is also listed in PubChem. Weight-based figures differ between salt and cation.
- Purity by HPLC (a method that separates a sample into its parts), with related impurities listed, for example the unmethylated starting material 5-aminoquinoline or other quinolinium by-products.
- Because this is not a peptide, peptide tests (amino acid sequence, peptide content) do not apply. A certificate that reports a peptide sequence for this compound is a warning sign.
- A lot-specific certificate tied to the batch number on the container, naming the testing laboratory and dated.
What is not known
- Does it do anything useful in people, and is it safe? It has never been tested in humans.
- How much reaches the blood when swallowed? Rat and mouse results disagree (about 38% versus 3.5%), and there are no human data.
- How much of its effect is from blocking NNMT and how much from its off-target block of MAO-A, reported in 2024?
- Would the results hold up in other labs? Nearly all metabolic and muscle studies of 5-amino-1MQ come from the UTMB group and Ridgeline Therapeutics, whose founder is an author. Independent groups have used it mainly in cancer cell and tumour studies.
- Was 5-amino-1MQ the compound used in the 2026 Cell Reports kidney study? The abstract does not say and the full text could not be opened.
- Did the 2017 structure-activity paper first describe 5-amino-1MQ itself? Its abstract does not name it; PubChem's synonym 'Compound 1k, NNMT inhibitor' hints that it did.
- Has Ridgeline Therapeutics started any human trial of an NNMT blocker? Its 2019 announcement said it was preparing one; none was found on ClinicalTrials.gov on 18 November 2026.
- Can 5-amino-1MQ legally be sold as a dietary supplement in the US? I found no FDA new dietary ingredient record or FDA statement either way.
Sources
All 27 sources
- PubChem: 5-amino-1-methylquinolinium, CID 950107 (formula, weight, CAS, synonyms). pubchem.ncbi.nlm.nih.gov
- PubChem: 5-amino-1-methylquinolinium iodide, CID 66522933. pubchem.ncbi.nlm.nih.gov
- Kraus et al. 2014, NNMT knockdown in mice (Nature). pubmed.ncbi.nlm.nih.gov
- Kannt et al. 2015, NNMT in human fat tissue and insulin resistance, 314 people (Diabetologia). pubmed.ncbi.nlm.nih.gov
- Neelakantan et al. 2017, structure-activity study of NNMT blockers. pubmed.ncbi.nlm.nih.gov
- Neelakantan et al. 2018, obese mice (Biochemical Pharmacology). pmc.ncbi.nlm.nih.gov
- Neelakantan et al. 2019, aged mouse muscle stem cells (Biochemical Pharmacology). pmc.ncbi.nlm.nih.gov
- Sampson et al. 2021, NNMT blocker plus lean diet in obese mice (Scientific Reports). pmc.ncbi.nlm.nih.gov
- Awosemo et al. 2021, rat blood levels and oral uptake. pubmed.ncbi.nlm.nih.gov
- Dimet-Wiley et al. 2024, aged female mice and exercise (Scientific Reports). pmc.ncbi.nlm.nih.gov
- Babula et al. 2024, obese mice, liver, MAO-A off-target (Diabetes, Obesity and Metabolism). pmc.ncbi.nlm.nih.gov
- Chanvillard et al. 2026, NNMT and chronic kidney disease (Cell Reports). pubmed.ncbi.nlm.nih.gov
- Bladder cancer study using 5-amino-1-methylquinolinium iodide in mice, 2024 (Journal for ImmunoTherapy of Cancer). pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov search for NNMT (no NNMT-blocker trials; searched 18 November 2026). clinicaltrials.gov
- FDA warning letter to GenoGenix LLC, 20 January 2026 (names 5-Amino-1MQ). fda.gov
- FDA: 503A nominated substances by category, updated 14 May 2026 (5-amino-1MQ not listed). fda.gov
- FDA: bulk drug substances that may present significant safety risks, current as of 22 April 2026 (not listed). fda.gov
- Electronic Code of Federal Regulations, 21 CFR 216.23 (503A bulks list; not listed). ecfr.gov
- Federal Register, 30 October 2026, 91 FR 68526: HHS draft peptide enforcement-discretion policy. govinfo.gov
- HHS policy with Appendix A (six peptides; 5-amino-1MQ not among them). hhs.gov
- WADA 2026 Prohibited List. wada-ama.org
- WADA news, 21 September 2026: 2027 Prohibited List. wada-ama.org
- WADA 2027 explanatory note (S0 and unnamed peptides). wada-ama.org
- Company announcement: Ridgeline Therapeutics press release, 19 February 2019 (RLT-72484; plans for human trials). prweb.com
- Ren 2026: 5-amino-1MQ reduced pancreatic scarring in mice. pubmed.ncbi.nlm.nih.gov
- Dong 2025: an unnamed NNMT inhibitor and leg-muscle strength in mice with blocked leg arteries. pubmed.ncbi.nlm.nih.gov
- Li 2025: NNMT inhibitor AMO-NAM (not 5-amino-1MQ) in aged mice with stiff-heart failure. pubmed.ncbi.nlm.nih.gov
Sources last checked 2026-11-18.
This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.